REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. on June 12, 2024. The filing discloses significant changes to the Company's executive leadership and board composition, effective July 1, 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- CEO Transition: Kenneth T. Mills resigned as President and Chief Executive Officer, effective July 1, 2024. He will continue to serve as a director and has been named Chairman of the Board.
- New CEO Appointment: Curran M. Simpson was appointed President and Chief Executive Officer, effective July 1, 2024. Mr. Simpson, previously the Chief Operating Officer since January 2023, will also serve as a Class I director.
- Board Changes: Daniel Tassé was appointed Lead Independent Director, succeeding Jerry Karabelas.
- Transition Support: Mr. Mills will serve as an advisor to the Company and the new CEO until June 30, 2025.
Compensation and Agreements
Curran M. Simpson (New CEO):
- Base salary: $610,000.
- Annual bonus target: Minimum 60% of base salary (prorated for 2024).
- Equity grant: Stock options and restricted stock units with an aggregate grant date fair value of $2,500,000 (approx. 75% options, 25% RSUs).
- Severance: Benefits provided for termination without cause, death, disability, or resignation for good reason following a change of control.
Kenneth T. Mills (Outgoing CEO):
- Consulting and Separation Agreement effective July 1, 2024, through June 30, 2025.
- Bonus: Eligible for up to 100% of targeted bonus for the fiscal year ending December 31, 2024.
- Equity: Outstanding stock options and RSUs will continue to vest during the advisory period; unvested awards will be forfeited thereafter. Options remain exercisable for three months post-advisory period.
- Benefits: Reimbursement of reasonable legal fees and COBRA coverage through January 30, 2025.
- Director Compensation: No initial equity grant for the Chairman role; eligible for cash and future annual equity awards per the Non-Employee Director program.
Guidance and Outlook
The Company issued a press release on June 12, 2024, reiterating its financial and operational guidance. Specific numerical guidance figures are not detailed within the text of this Form 8-K.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the reiterated financial and operational guidance.
- Verify the exact vesting schedules and performance conditions for Mr. Simpson's $2.5 million equity grant in the full Employment Agreement.
- Confirm the specific terms of the "good reason" resignation clause in Mr. Simpson's agreement.
- Monitor the Company's upcoming filings for the impact of the leadership transition on clinical development timelines and commercial strategy.